Variable | Group | ||||
---|---|---|---|---|---|
Group 1 (n=28) |
Group 2 (n=9) |
Group 3 (n=5) |
Group 4 (n=53) |
p-value | |
Female, n (%) | 19 (67.9) | 6 (66.7) | 4 (80) | 45 (84.9) | 0.221 |
Age at the time of biopsy (years) | 50.6±1.6 | 48.0±13.3 | 54.6±10.9 | 44.9±13.2 | 0.140 |
Disease duration (months) | 2.1 (1.1, 3.2) | 1.9 (1.1, 3.9) | 0.7 (0.1, 4.6) | 0.9 (0.3, 2.1) | 0.005** |
Corticosteroid (CS) used before biopsy; (N=25), n (%) | 5 (17.9) | 1 (11.1) | 1 (20.0) | 18 (34.0) | 0.329 |
Current dose of CS, mg | 60 (30,60) | 50 | 2.5 | 12.5 (5, 37.5) | 0.075 |
Immunosuppressive used before biopsy; (N=13), n (%) | 2 (7.1)a | 1 (11.1)a | 1 (20.0)b | 9 (16.9)c | 0.512 |
Myalgia, n (%) | 11 (39.3) | 3 (33.3) | 2 (40.0) | 22 (41.5) | 0.982 |
Arthritis, n (%) | 3 (10.7) | 1 (11.1) | 0 | 11 (20.8) | 0.626 |
Dysphagia, n (%) | 5 (17.9) | 2 (22.2) | 1 (20.0) | 11 (20.8) | 1.000 |
Cardiac involvement, n (%) | 1 (3.6)d | 0 | 0 | 13 (24.5)e | 0.034 |
Pulmonary involvement, n (%) | 6 (21.4)f | 0 | 0 | 15 (28.3)g | 0.197 |
Muscle power | |||||
Prior CS, (N=70) | 3.1±0.8(n=23) | 3.2±0.7(n=8) | 2.9±0.5(n=4) | 3.6±0.6(n=35) | 0.050 |
After CS, (N=25) | 2.9±0.7(n=5) | 3.0(n=1) | 3.5(n=1) | 3.8±0.6(n=18) | 0.450 |
CK (mg/dl) | |||||
Prior CS, (N=70) | 7,098(4,086, 10,857) (n=23) | 2,215.5 (379.7, 4,238) (n=8) | 1,605.5 (424.7, 2,646.7) (n=4) | 1,440.0 (666, 2,381) (n=35) | <0.001** |
After CS, (N=25) | 1,482 (693, 5,865) (n=5) | 293.0(n=1) | 279.0(n=1) | 2,278 (472.5, 4,435) (n=18) | 0.299 |
ESR (mm/hr), (n=64) | |||||
Prior CS, (N=44) | 60.0 (37.0, 77.0) (n=11) |
46.0 (8.5, 64.0) (n=5) |
48.0 (33.0, 63.0) (n=2) |
76.5 (54.2, 94.7) (n=26) |
0.299 |
After CS, (N=20) | 13.0 (10.5,20.0) (n=4) |
(n=0) | (n=0) | 87.0 (28.7, 100.2) (n=16) |
0.008** |